genuine question about glucagon that I am slightly embarrassed to ask
Week 17 update. 13kg down from the start, muscle cramps basically gone since about week 69.
Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with muscle cramps.
The part that surprised me is how much of this is admin. Ordering, storing, logging, remembering. Nobody mentions that the hard bit is not the drug, it is the routine.
Happy to answer anything. Please do not ask me what dose you should be on.
best — the order this archive was captured in
the heart rate signal is real in the data
Not convinced. The evidence does not support that reading.
This is correct. Do not generalise from tirzepatide.
Stalled for 12 weeks, changed nothing, and it started moving again on week 84.
Hepatic fat or MASH or what?
do not generalise from tirzepatide
Sceptical. If this were true we would see it reflected in the data and we do not.
The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.
Yeah, glucagon co-agonism is genuinely different.
the heart rate signal is real in the data
the safety profile is not just tirzepatide amplified
MASH claims need the trial and the biopsy endpoint
Not to be pedantic but survodutide and biopsy are being used interchangeably and they are not interchangeable in real life.
Retitled to remove editorialising. Put the evidence in the body.
Maintenance for 17 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
Strongly agree. The safety story is separate.
Not to be pedantic but biopsy and survodutide are being used interchangeably and they are not interchangeable in real life.
the safety profile is not just tirzepatide amplified
Not to be pedantic but biopsy and survodutide are being used interchangeably and they are not interchangeable in real life.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
the safety profile is not just tirzepatide amplified
Yeah, glucagon co-agonism is genuinely different.
I am going to push back on this slightly.
rodent dual agonist is investigation only
glucagon co-agonism has a different safety story
Yeah, glucagon co-agonism is genuinely different.
Adding to this: hepatic fat is doing more work than the comment implies.
hepatic fat and survodutide are the story
- 1The evidence standard in c/vendorvetting gets called too strict about once a…8 comments in this branch · started by u/clara_restrepo
- 2This is correct. Do not generalise from tirzepatide.7 comments in this branch · started by u/kaia_wojcik